| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
83,810,000 |
| Market
Cap: |
10.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0375 - $6.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co.'s reportable segments include: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
328,000 |
403,000 |
403,000 |
439,133 |
| Total Buy Value |
$12,978,125 |
$15,790,625 |
$15,790,625 |
$16,096,924 |
| Total People Bought |
1 |
1 |
1 |
4 |
| Total Buy Transactions |
3 |
4 |
4 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sulat James R |
Director |
– • – |
2023-03-15 |
4 |
B |
$8.54 |
$128,156 |
D/D |
15,000 |
82,553 |
2.39 |
-95% |
|
| Bisaro Paul |
Director |
– • – |
2023-03-14 |
4 |
B |
$8.47 |
$42,330 |
D/D |
5,000 |
74,820 |
2.39 |
-95% |
|
| Sulat James R |
Director |
– • – |
2023-03-14 |
4 |
B |
$8.42 |
$126,320 |
D/D |
15,000 |
67,553 |
2.39 |
-95% |
|
| Richardson Peter C |
EVP & Chief Scientific Officer |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
75,091 |
75,091 |
|
- |
|
| El-Dada Riad Hussein |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Goldman Neal P |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Celentano Daniel Arthur |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Bisaro Paul |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
39,083 |
69,820 |
|
- |
|
| Silbermann Susan Michele |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Ling Karen |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Sulat James R |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Myers Woodrow A Jr |
Director |
– • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,277 |
52,553 |
|
- |
|
| Olafsson Sigurdur O |
President and CEO |
• • – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
225,272 |
225,272 |
|
- |
|
| Reasons Bryan M. |
EVP & CFO |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
112,636 |
112,636 |
|
- |
|
| Goodson Jason Daniel |
EVP & Head of Corp Development |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,545 |
37,545 |
|
- |
|
| Harrold Kassie |
Chief Compliance Officer |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,545 |
37,545 |
|
- |
|
| Tyndall Mark Anthony |
EVP & Chief Legal Offi & Secre |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,091 |
75,091 |
|
- |
|
| Welch Stephen Andrew |
EVP & Head of Spec Generics |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
37,545 |
37,545 |
|
- |
|
| French Lisa |
EVP & Chief Commercial Officer |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,091 |
75,091 |
|
- |
|
| Nielsen Henriette |
EVP & Chief Transformation OFC |
• – – |
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
75,091 |
75,091 |
|
- |
|
| Olifant Luxco S.a R.l. |
10% Owner |
– – • |
2022-06-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,033,257 |
|
- |
|
| Casey Mark J |
EVP & Chief Legal Officer |
• – – |
2022-06-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,011) |
0 |
|
- |
|
| Carter Paul Rutherford |
Director |
– • – |
2022-06-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,320) |
0 |
|
- |
|
| Harrold Kassie |
Chief Compliance Officer |
• – – |
2022-06-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(118) |
0 |
|
- |
|
| Oneill Hugh M. |
See Remarks |
• – – |
2022-06-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(76,856) |
0 |
|
- |
|
627 Records found
|
|
Page 3 of 26 |
|
|
